With the development of high-throughput sequencing technology, many potential biomarkers related to the diagnosis and prognosis for treatment decision making of glioblastoma have been found, such as MGMT (O6 methylguanine DNA methyltransferase), H3F3A (H3 histone, family 3A), IDH (isocitrate dehydrogenase), EGFR (epidermal growth factor receptor), and PTEN (phosphatase and tensin homolog) [7,8,9,10,11]. This evidence concerns the gene MGMT and glioblastoma.